Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced it has initiated its first-in-human Phase I clinical trial for ATI-2173, a novel liver-targeted, orally-administered, small molecule against hepatitis B.
February 3, 2020
An antiviral compound discovered at Emory University could potentially be used to treat the new coronavirus associated with the outbreak in China and spreading around the globe.
October 23rd 2019
A new drug that has shown promise
Drug Innovation Ventures at Emory (DRIVE) and Antios Therapeutics announce license for hepatitis B drug
December 4, 2018
Antios raises $25 million in Series A financing
October 24, 2017
January 30th, 2017
Georgia Bio has honored Abel De La Rosa, PhD, chief scientific officer of Drug Innovation Ventures at Emory (DRIVE) and the Emory Institute for Drug Development (EIDD) with a 2017 Community Award.
David Perryman of Drug Innovation Ventures at Emory (DRIVE) and the Emory Institute for Drug Development discusses the institute and how it ranks nationwide.
DRIVE CEO George Painter hiking in Death Valley, California- pictured in Spring, 2016 furthering DRIVE’s mission by bridging the Valley of Death.
February 19th, 2016
More than 20 scientists with two drug development groups at Emory University are working to develop a treatment for the Zika virus.